Abivax Shares Climb 4.74% to €110.50 Following $45M Fundraising
The French biotech continues its ascent this Wednesday morning. The stock is up 4.74% at €110.50, after closing at €105.50 the previous day. The increase follows the announcement of the repurchase of royalty certificates and the raising of $45 million in ADS.
Abivax (FR0012333284) has surpassed its technical resistance at €109.40, previously tested in mid-April following Oddo BHF's target upgrade. The price is now above the upper Bollinger band set at €109.15, indicating an overbought condition. The RSI, at 57, remains in the neutral zone, suggesting that the buying pressure is not yet at an extreme level. The 50-day moving average is at €100.91, about 9% below the current price. The annual performance exceeds 1,650%, and the stock has gained 15.65% over the week. This movement extends the reaction to the repurchase of royalty certificates announced on Tuesday.
Financial Visibility Until Q4 2027 and Clinical Schedule
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
During the third quarter 2025 report, the company indicated it had the means to fund its cash needs until the fourth quarter of 2027. This autonomy was further strengthened by the recent ADS operation, which raised €38.5 million. Highlights of this publication included the progress of phase 3 trials of Obefazimod in ulcerative colitis. The Digestive Disease Week congress, held in Chicago until May 5, featured nine scientific presentations on the molecule. The company also reiterated the inherent risks associated with clinical development and decisions by regulatory authorities (FDA, EMA). The CAC 40 is up 1.56% at 8,187.98 points during the session. The next financial calendar event is the release of the first quarter 2026 results, scheduled for June 1.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
